Summary
Carnitine is an essential factor for the transport of long-chain fatty acids and is important for the heart muscle. A longitudinal study in type 2 diabetic patients was carried out. Carnitine levels were observed before and during metabolic intervention with dietary measures and either sulfonylurea or insulin treatment. In both treatment groups a significant glycemic improvement was observed after 3 months (insulin treatment group hemoglobin A1c 11.3 ± 2.8 versus 7.0±1.0; sulfonylurea treatment group; hemoglobin A1c 11.3±1.4 versus 7.3±0.9). Carnitine levels did not differ from a control group and did not change significantly during the observed period.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- FC:
-
free carnitine
- TC:
-
total carnitine
- AC:
-
acyl carnitine
- HbA1c :
-
hemoglobin A1c
References
Bahl J, Bressler R (1987) The pharmacology of carnitine. Annu Rev Pharmacol Toxicol 27:257–277
Böhmer T, Rydning A, Solberg HE (1974) Carnitine levels in human serum in health and disease. Clin Chim Acta 57:55–61
Capaldo B (1991) Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 14:191–195
Cederblad G, Lindstedt S (1972) A method for the determination of carnitine in the picomole range. Clin Chim Acta 37:235–243
Cederblad G, Hermansson G, Ludvigsson J (1982) Plasma and urine carnitine in children with diabetes mellitus. Clin Chim Acta 125:207–217
Corr PB, Creer MH, Yamada KA, Saffitz JE, Sobel BE (1989) Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 83:927–936
De Palo E, Gatti R, Sicolo N, Padovan D, Vettor R, Federspil G (1981) Plasma and urine free L-carnitine in human diabetes mellitus. Acta Diabetol Lat 18:91–95
Duan J, Karmazyn M (1989) Effect of D,L-carnitine on the response of the isolated heart of the rat to ischaemia and reperfusion: relation to mitochondrial function. Br J Pharmacol 98:1319–1327
Editorial (1990) Carnitine deficiency. Lancet I: 631–633
Ferrannini E, Buzzigoli G, Bevilacqua S, Boni C, Del Chiaro D, Oleggini M, Brandi L, Maccari F (1988) Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol 255:E946-E952
Friedewald WT, Levy RI, Friedrickson TS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 18:499
Genuth SM, Hoppel CL (1979) Plasma and urine carnitine in diabetic ketosis. Diabetes 28:1083–1087
Holme E, Greter J, Jacobson CE, Lindstedt S, Nordin I, Kristiansson B, Jodal U (1989) Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet II:469–472
Ino T, Sherwood WG, Cutz E, Benson LE, Rose V, Freedom RM (1988) Dilated cardiomyopathy with neutropenia, short stature and abnormal carnitine metabolism. Pediatrics 113:511–514
Lohninger A, Kaiser E, Legenstein E, Staniek H (1987) Carnitine, metabolism and function. In: Kaiser E, Lohninger A (eds) Carnitine — its role in lung and heart disorders. Karger, Basel New York, pp 1–25
Lopaschuk GD, Wall SR, Olley PM, Davies NJ (1988) Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischaemic injury independent of changes in long-chain acylcarnitine. Circ Res 63:1036–1043
McGarry JD, Mannaerts GP, Foster DW (1977) A possible role for Malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 60:265–270
Pregant P, Schernthaner G, Legenstein E, Lienhart L, Bruck S, Schnack C, Kaiser E (1991) Vermindertes Plasmacarnitin bei Typ-I Diabetes mellitus. Klin Wochenschr 69:511–516
Rodrigues B, Xiang H, McNeill JH (1988) Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37:1358–1364
Rösen P, Reinauer H (1984) Inhibition of Carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats. Metabolism 33:177–185
Scholte HR, Luyt-Howen IEM, Vaandrager-Verduin MHM (1987) The role of carnitine system in myocardial fatty acid oxidation: carnitine deficiency, failing mitochondria and cardiomyopathy. Basic Res Cardiol 82 [Suppl 1]:63–73
Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM (1988) Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle and fibroblasts. N Engl J Med 319:1331–1335
Vary TC, Neely JR (1982) A mechanism for reduced myocardial carnitine levels in diabetic animals. Am J Physiol 243:H154–158
Winder WW, Arogyasami J, Elayan IM, Cartmill D (1990) Time course of exercise-induced decline in malonyl-CoA in different muscle types. Am J Physiol 259:E266-E271
Winter SC, Simon M, Zorn ME, Szabo-Aczel S, Vance W, O'Hara T, Higashi L (1989) Relative carnitine insufficiency in children with type I diabetes mellitus. Am J Dis Child 143:1337–1339
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pregant, P., Kaiser, E. & Schernthaner, G. No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients. Clin Investig 71, 610–612 (1993). https://doi.org/10.1007/BF00184484
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00184484